Cargando…
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
Testosterone is the canonical growth factor of prostate cancer but can paradoxically suppress its growth when present at supraphysiological levels. We have previously demonstrated that the cyclical administration of supraphysiological androgen (SPA), termed bipolar androgen therapy (BAT), can result...
Autores principales: | Sena, Laura A., Kumar, Rajendra, Sanin, David E., Thompson, Elizabeth A., Rosen, D. Marc, Dalrymple, Susan L., Antony, Lizamma, Yang, Yuhan, Gomes-Alexandre, Carolina, Hicks, Jessica L., Jones, Tracy, Bowers, Kiara A., Eskra, Jillian N., Meyers, Jennifer, Gupta, Anuj, Skaist, Alyza, Yegnasubramanian, Srinivasan, Luo, Jun, Brennen, W. Nathaniel, Kachhap, Sushant K., Antonarakis, Emmanuel S., De Marzo, Angelo M., Isaacs, John T., Markowski, Mark C., Denmeade, Samuel R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711876/ https://www.ncbi.nlm.nih.gov/pubmed/36194476 http://dx.doi.org/10.1172/JCI162396 |
Ejemplares similares
-
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer
por: Denmeade, Samuel R, et al.
Publicado: (2023) -
Bipolar androgen therapy (BAT): A patient's guide
por: Denmeade, Samuel, et al.
Publicado: (2022) -
Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2(nd) generation androgen receptor signaling inhibitors
por: Zhu, Yezi, et al.
Publicado: (2020) -
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer
por: Brennen, W. Nathaniel, et al.
Publicado: (2021) -
Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss
por: Markowski, Mark C., et al.
Publicado: (2022)